Search

Kerstin Leuther Phones & Addresses

  • 4805 Quimby Rd, San Jose, CA 95148
  • 3802 La Donna Ave, Palo Alto, CA 94306 (650) 856-1215
  • 3895 La Donna Ave, Palo Alto, CA 94306 (650) 856-1215
  • 26982 Beaver Ln, Los Altos, CA 94022 (650) 856-1215
  • Los Altos Hills, CA
  • Dallas, TX

Publications

Us Patents

Erythropoietin Receptor Peptide Formulations And Uses

View page
US Patent:
7906485, Mar 15, 2011
Filed:
Jun 5, 2006
Appl. No.:
11/916416
Inventors:
Anne-Marie Duliege - Palo Alto CA,
Richard Stead - Bellevue WA,
Kerstin Leuther - San Jose CA,
Kathryn Wynne Woodburn - Campbell CA,
Robert Barnett Naso - Menlo Park CA,
Assignee:
Affymax, Inc. - Palo Alto CA
International Classification:
A61K 38/10
A61K 38/16
US Classification:
514 135, 514 214
Abstract:
The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production, including pure red cell aplasia (PRCA). Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.

Erythropoietin Receptor Peptide Formulations And Uses

View page
US Patent:
7919461, Apr 5, 2011
Filed:
Jul 13, 2007
Appl. No.:
11/777500
Inventors:
Anne-Marie Duliege - Palo Alto CA,
Richard Stead - Bellevue WA,
Kerstin Leuther - San Jose CA,
Kathryn Wynne Woodburn - Campbell CA,
Robert Barnett Naso - Menlo Park CA,
Assignee:
Affymax, Inc. - Palo Alto CA
International Classification:
A61K 38/16
US Classification:
514 12
Abstract:
The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.

Erythropoietin Receptor Peptide Formulations And Uses

View page
US Patent:
8324159, Dec 4, 2012
Filed:
Jul 23, 2008
Appl. No.:
12/178583
Inventors:
Anne-Marie Duliege - Palo Alto CA,
Richard Stead - Bellevue WA,
Kerstin Leuther - San Jose CA,
Kathryn Wynne Woodburn - Saratoga CA,
Robert Barnett Naso - Menlo Park CA,
Assignee:
Affymax, Inc. - Palo Alto CA
International Classification:
A61K 38/16
US Classification:
514 77, 514 54, 514 135, 514 154, 514 214
Abstract:
The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.

High Throughput Polymorphism Screening

View page
US Patent:
2003008, May 1, 2003
Filed:
May 6, 2002
Appl. No.:
10/139480
Inventors:
Keith Jones - Sunnyvale CA,
Kerstin Leuther - Palo Alto CA,
Michael Shapero - Redwood City CA,
International Classification:
C12Q001/68
C12P019/34
US Classification:
435/006000, 435/091200
Abstract:
Methods are provided for determining the identity of a polymorphic nucleotide in a complex mixture of nucleic acids where one or more distinct polymorphisms can be present in the mixture, and multiple polymorphisms can be screened in parallel. Target nucleic acids are amplified using bridge amplification techniques. The detection and identification of the specific polymorphic residue(s) is based on readout methods that utilize the specificity of specific enzymes for complementary DNA sequences. These approaches result in a labeled nucleotide covalently attached to the amplicon, where the identity of the nucleotide is informative of the polymorphic sequence. In one aspect, the readout process uses primer extension protocols, where the specific base incorporated by DNA polymerase is determined by the sequence at the polymorphic site. In another aspect, the identity of a specific base hybridized and ligated to the amplicon is determined by the sequence at the polymorphic site. The polynucleotide to which the label has been attached can be detected in situ, i.e. bound to the solid substrate used for amplification; or can be released and detected.

Erythropoietin Receptor Peptide Formulations And Uses

View page
US Patent:
2007010, May 10, 2007
Filed:
Jun 2, 2006
Appl. No.:
11/446593
Inventors:
Anne-Marie Duliege - Palo Alto CA,
Richard Stead - Bellevue WA,
Kerstin Leuther - Palo Alto CA,
Kathryn Woodburn - Campbell CA,
Robert Naso - Menlo Park CA,
Assignee:
Affymax, Inc. - Palo Alto CA
International Classification:
A61K 38/48
US Classification:
424094640
Abstract:
The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.

Erythropoitein Receptor Peptide Formulations And Uses

View page
US Patent:
2013007, Mar 28, 2013
Filed:
Nov 27, 2012
Appl. No.:
13/686245
Inventors:
Richard Stead - Bellevue WA,
Kerstin Leuther - San Jose CA,
Kathryn Wynne Woodburn - Saratoga CA,
Robert Barnett Naso - Menlo Park CA,
Assignee:
AFFYMAX, INC. - Palo Alto CA
International Classification:
C07K 17/08
US Classification:
514 135
Abstract:
The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.
Kerstin K Leuther from San Jose, CA, age ~53 Get Report